Back to Journals » Journal of Pain Research » Volume 11

Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice

Authors Ho KY, Gwee KA, Cheng YK, Yoon KH, Hee HT, Omar AR

Received 14 March 2018

Accepted for publication 27 July 2018

Published 20 September 2018 Volume 2018:11 Pages 1937—1948


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Erica Wegrzyn

Kok Yuen Ho,1 Kok Ann Gwee,2 Yew Kuang Cheng,3,4 Kam Hon Yoon,5 Hwan Tak Hee,6 Abdul Razakjr Omar7

1The Pain Clinic, Mt Alvernia Hospital, 2Stomach, Liver, and Bowel Centre, Gleneagles Hospital, 3Farrer Park Hospital, 4Yong Loo Lin School of Medicine, National University of Singapore, 5El Shaddai Arthritis and Rheumatism Specialist Medical Centre, 6Pinnacle Spine and Scoliosis Centre, Mt Elizabeth Medical Centre, 7Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

Abstract: COX2-selective and nonselective (ns) nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for chronic pain management. There are marked differences in the risk of adverse gastrointestinal (GI) and cardiovascular (CV) events among different NSAIDs. In 2017, publication of two randomized controlled trials and an individual patient-data meta-analysis provided robust data on the relative GI and CV tolerability profiles of currently available NSAIDs. The PRECISION study showed similar CV-event rates with celecoxib vs naproxen and ibuprofen, but GI tolerability was better for celecoxib. In the CONCERN study of high-GI-risk patients, celecoxib was associated with fewer adverse GI-tract events than naproxen. The meta-analysis showed no significant difference between celecoxib and ns-NSAIDs in the rate of acute myocardial infarction, and celecoxib was the only COX2-selective NSAID with a lower risk of adverse CV and GI events vs ns-NSAIDs. These data add to the body of knowledge about the relative tolerability of different NSAIDs and were used to propose an updated treatment algorithm. The decision about whether to use an NSAID and which one should be based on a patient’s risk of developing adverse GI and CV events. Lower- and upper-GI-tract events need to be considered. Celecoxib has a better lower-GI-tract tolerability profile than ns-NSAIDs plus a proton-pump inhibitor. In addition, the latest data suggest that long-term use of celecoxib 200 mg/day may be appropriate for patients at increased CV risk.

Keywords: nonsteroidal anti-inflammatory drugs, chronic pain, COX2 inhibitors, cardiovascular risk, gastrointestinal risk

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]